The upcoming therapy, Rifaximin (SSD), has the potential to create a significant positive shift in the Overt Hepatic Encephalopathy market size. Topline data of Phase II study for the treatment
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis announces new organizational structure to accelerate growth, strengthen pipeline and increase productivity
Axcella Health Inc. (NASDAQ:AXLA – Get Rating) – Equities research analysts at SVB Leerink issued their Q1 2022 earnings estimates for Axcella Health in a research report issued on Wednesday, March 30th. SVB Leerink analyst T. Smith anticipates that the company will post earnings of ($0.42) per share for the quarter. SVB Leerink currently has […]
Major drug companies, including leading COVID-19 vaccine developers, have joined efforts to discover a potential treatment for long COVID, a condition affecting over 100 million.
Axcella Health Inc. (NASDAQ:AXLA – Get Rating) CEO William Hinshaw purchased 13,089 shares of Axcella Health stock in a transaction dated Wednesday, March 16th. The stock was bought at an average price of $1.91 per share, with a total value of $24,999.99. The acquisition was disclosed in a document filed with the Securities & Exchange […]